RayKnowChina Research Map
Shortlist0

ChongqingArmy Medical University

Southwest Hospital, Army Medical University

陆军军医大学第一附属医院(西南医院)

Listed for 20 of the 53 diseases this site covers, from the research papers it led and the trials registered with it as lead sponsor or site.

Research activity in public records, not a rating of care. Whether the hospital can help a particular patient is for the hospital and the treating doctor to say.

No official website checked for this hospital yet.

Getting in touch

Research at Southwest Hospital, Army Medical University

Choose a disease to see the papers and trials behind it. Each tile shows papers led, 2021–2025, and papers per year.

Only the 53 diseases this site covers. A disease it is not listed for means this hospital did not meet the listing rule for that disease in these records; it does not mean the hospital does not treat it. Which hospitals are listed

  1. Nasopharyngeal carcinoma鼻咽癌3 papers led
  2. Oesophageal squamous cell carcinoma食管鳞状细胞癌0 papers led
  3. Hepatocellular carcinoma肝细胞癌57 papers led
  4. Stomach cancer胃癌23 papers led2 open trials led
  5. Osteosarcoma骨肉瘤7 papers led
  6. Gastrointestinal stromal tumour胃肠道间质瘤1 paper led
  7. Neuroblastoma神经母细胞瘤0 papers led
  8. Multiple myeloma多发性骨髓瘤0 papers led
  9. Aplastic anaemia再生障碍性贫血2 papers led
  10. Haemophagocytic lymphohistiocytosis噬血细胞性淋巴组织细胞增生症2 papers led
  11. Atypical haemolytic uraemic syndrome非典型溶血性尿毒症综合征0 papers led
  12. Fanconi anaemia范可尼贫血1 paper led
  13. Moyamoya disease烟雾病2 papers led
  14. Amyotrophic lateral sclerosis肌萎缩侧索硬化症1 paper led
  15. Duchenne muscular dystrophy杜氏肌营养不良0 papers led
  16. Behçet disease白塞病1 paper led
  17. IgA nephropathyIgA 肾病0 papers led
  18. Primary biliary cholangitis原发性胆汁性胆管炎5 papers led
  19. Primary sclerosing cholangitis原发性硬化性胆管炎1 paper led
  20. Inherited epidermolysis bullosa遗传性大疱性表皮松解症0 papers led

Not listed for: Hepatoblastoma, Retinoblastoma, Chordoma, Ewing sarcoma, B-cell acute lymphoblastic leukaemia, Beta thalassaemia, Haemophilia A, Thrombotic thrombocytopenic purpura, Neuromyelitis optica spectrum disorder, IgG4-related disease, Myasthenia gravis, Wilson disease, Biliary atresia, Anti-NMDA receptor encephalitis, Takayasu arteritis, Hepatic echinococcosis, Idiopathic pulmonary fibrosis, Lymphangioleiomyomatosis, Spinal muscular atrophy, Fabry disease, Pompe disease, Alport syndrome, Gaucher disease, Niemann–Pick disease type C, Osteogenesis imperfecta, Congenital diaphragmatic hernia, Hirschsprung disease, Hereditary angioedema, Familial adenomatous polyposis, Leber hereditary optic neuropathy, Majeed syndrome, NGLY1 deficiency, ISG15 deficiency.

Cancer

Nasopharyngeal carcinoma

鼻咽癌

Led 3 of the 2,375 English-language PubMed papers on nasopharyngeal carcinoma with an author in mainland China, 2021–2025: 0.1%.

Papers led
3
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 1120242025: 002025

6 hospitals in Chongqing for nasopharyngeal carcinoma176 hospitals in China for nasopharyngeal carcinoma

No open trial on nasopharyngeal carcinoma lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesRadiotherapy technique
Departments in papersMedical oncology

Run the PubMed searchClinicalTrials.gov

Cancer

Oesophageal squamous cell carcinoma

食管鳞状细胞癌

Led no English-language PubMed papers on oesophageal squamous cell carcinoma in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

7 hospitals in Chongqing for oesophageal squamous cell carcinoma191 hospitals in China for oesophageal squamous cell carcinoma

No open trial on oesophageal squamous cell carcinoma lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Cancer

Hepatocellular carcinoma

肝细胞癌

Led 57 of the 14,765 English-language PubMed papers on hepatocellular carcinoma with an author in mainland China, 2021–2025: 0.4%.

Papers led
57
2021–2025
Trials led
19
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
2
led by another institution
Papers led per year
2021: 9920212022: 101020222023: 131320232024: 131320242025: 10102025

5 hospitals in Chongqing for hepatocellular carcinoma192 hospitals in China for hepatocellular carcinoma

Open trials with this hospital 2

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Digital Early Warning System for Acute Lung Injury in Liver Surgery
    Phase
    Not given
    Started
    2024-11
    Registry
    NCT07070362

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesBeijing, Chongqing

  2. Not yet recruiting
    Comparison of ultraSound, Abbreviated MRI witH and Without HBP aS mOdalities for HCC suRveillance in patienTs With High Risk
    Phase
    N/A
    Started
    2025-06
    Registry
    NCT07010588

    Age 18 years to 75 years (registered criteria)

    Led by Peking University People's Hospital; 8 listed hospitals as study sitesBeijing, Changchun, Chongqing, Harbin, Jinan, Qingdao, Wuhan, Xi'an

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesSurgery & liver transplantRecurrence & prognosisLocal treatment (ablation, TACE, HAIC)
Departments in papersSurgery (general/hepatobiliary/pancreatic)Radiology / nuclear medicineGastroenterology / hepatologyPathology / laboratory medicine
Papers it led57
  1. Noninvasive MRI imaging feature-based prediction of intratumoral tertiary lymphoid structure maturity in hepatocellular carcinoma: a multicenter retrospective study.2026European radiology
  2. Different approaches of laparoscopic anatomic hepatectomy of segment 7 for hepatocellular carcinoma: A multicenter study.2026Hepatobiliary & pancreatic diseases international : HBPD INT
  3. Chronic stress impacts the prognosis of hepatocellular carcinoma patients after curative treatment by establishing a novel comprehensive classification: a cohort study and systematic review.2025BMC psychiatryFree full text
  4. Effect of Electric Fields on the Mechanical Mechanism of Regorafenib-VEGFR2 Interaction to Enhance Inhibition of Hepatocellular Carcinoma.2025BiomoleculesFree full text
  5. Dynamic Profiles of Internal m7G Methylation on mRNAs in the Progression from HBV Infection to Hepatocellular Carcinoma.2025Digestive diseases and sciences
  6. A novel hybrid model for predicting tertiary lymphoid structures and targeted immunotherapy outcomes in hepatocellular carcinoma: a multicenter retrospective study.2025European radiology
  7. Integrated ubiquitomics characterization of hepatocellular carcinomas.2025Hepatology (Baltimore, Md.)
  8. The immune-reinforcements of Lenvatinib plus anti-PD-1 and their rationale to unite with TACE for unresectable hepatocellular carcinoma treatment.2025Immunology letters
  9. Subsegmental radiofrequency ablation: a novel ablation technique based on portal territory for treatment of hepatocellular carcinoma.2025International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group
  10. Indocyanine green fluorescence staining-guided laparoscopic posterosuperior segmentectomy: A multicenter retrospective cohort study.2025Surgical endoscopy
  11. TGF-β induces a decrease in CAPZA1 expression to promote the invasiveness of hepatocellular carcinoma cells.2025The American journal of the medical sciences
  12. Intersegmental veins between segments 5 and 8 as a landmark along the intersegmental planes during laparoscopic anatomical segmentectomy for hepatocellular carcinoma.2025Updates in surgery
  13. The Taping Game for the Complex G8 Glissonean Approach Is the Most Effective Technique for Laparoscopic Anatomic S8 Resection of Dandelion-Patterned Hepatic Pedicles.2024Annals of surgical oncology
  14. Indocyanine Green Fluorescence-Guided Laparoscopic Anatomical Segmentectomy of Liver Segment 6: Surgical Strategy and Technical Details.2024Annals of surgical oncology
  15. The efficacy and safety of Radiofrequency ablation combined with Lenvatinib plus Sintilimab in Unresectable Hepatocellular Carcinoma: a real-world study.2024BMC cancerFree full text
  16. Aptamer-bivalent-cholesterol-mediated proximity entropy-driven exosomal protein reporter for tumor diagnosis.2024Biosensors & bioelectronics
  17. Integrative multiomics analysis identifies molecular subtypes and potential targets of hepatocellular carcinoma.2024Clinical and translational medicineFree full text
  18. Upregulation of miR-3130-5p Enhances Hepatocellular Carcinoma Growth by Suppressing Ferredoxin 1 : miR-3130-5p Enhances HCC Growth via Inhibiting FDX1.2024Current molecular pharmacology
  19. Elevated expression of WSB2 degrades p53 and activates the IGFBP3-AKT-mTOR-dependent pathway to drive hepatocellular carcinoma.2024Experimental & molecular medicineFree full text
  20. Berberine increases the killing effect of pirarubicin on HCC cells by inhibiting ATG4B-autophagy pathway.2024Experimental cell research
  21. Oxyberberine sensitizes liver cancer cells to sorafenib via inhibiting NOTCH1-USP7-c-Myc pathway.2024Hepatology communicationsFree full text
  22. Anatomic Liver Resection Based on Portal Territory With Margin Priority for Hepatocellular Carcinoma.2024JAMA surgery
  23. Evaluation and Prognostication of Gd-EOB-DTPA MRI and CT in Patients With Macrotrabecular-Massive Hepatocellular Carcinoma.2024Journal of magnetic resonance imaging : JMRI
  24. LHX3 promotes EMT in hepatoma cell through β-catenin/TCF4 pathway.2024Medical oncology (Northwood, London, England)
  25. Integrative multiomic analysis identifies distinct molecular subtypes of NAFLD in a Chinese population.2024Science translational medicine
  26. A Smart Nano-Theranostic Platform Based on Dual-microRNAs Guided Self-Feedback Tetrahedral Entropy-Driven DNA Circuit.2023Advanced science (Weinheim, Baden-Wurttemberg, Germany)Free full text
  27. FBXW10-S6K1 promotes ANXA2 polyubiquitination and KRAS activation to drive hepatocellular carcinoma development in males.2023Cancer letters
  28. Long-term efficacy of no-touch radiofrequency ablation in the treatment of single small hepatocellular carcinoma: A single center long-term follow-up study.2023Cancer medicineFree full text
  29. Semaphorin 7A interacts with nuclear factor NF-kappa-B p105 via integrin β1 and mediates inflammation.2023Cell communication and signaling : CCSFree full text
  30. Elevated FBXW10 drives hepatocellular carcinoma tumorigenesis via AR-VRK2 phosphorylation-dependent GAPDH ubiquitination in male transgenic mice.2023Cell reports
  31. Elevated FBXL6 expression in hepatocytes activates VRK2-transketolase-ROS-mTOR-mediated immune evasion and liver cancer metastasis in mice.2023Experimental & molecular medicineFree full text
  32. Elevated FBXL18 promotes RPS15A ubiquitination and SMAD3 activation to drive HCC.2023Hepatology communicationsFree full text
  33. Effects of iodine-125 seed brachytherapy on patients with heterochronous pulmonary metastasis from hepatocellular carcinoma: A propensity score matching study.2023Journal of cancer research and therapeutics
  34. Open Radiofrequency Ablation Combined with Splenectomy and Pericardial Devascularization vs. Liver Transplantation for Hepatocellular Carcinoma Patients with Portal Hypertension and Hypersplenism: A Case-Matched Comparative Study.2023Journal of investigative surgery : the official journal of the Academy of Surgical Research
  35. Degradation of helicase-like transcription factor (HLTF) by β-TrCP promotes hepatocarcinogenesis via activation of the p62/mTOR axis.2023Journal of molecular cell biologyFree full text
  36. Elevated FBXL6 activates both wild-type KRAS and mutant KRASG12D and drives HCC tumorigenesis via the ERK/mTOR/PRELID2/ROS axis in mice.2023Military Medical ResearchFree full text
  37. In vivo analysis of FBXO45-mediated fibrosis and liver tumorigenesis in a chemically induced mouse model of hepatocellular carcinoma.2023STAR protocolsFree full text
  38. Intermittent Pringle maneuver combined with controlled low Central venous pressure prolongs hepatic hilum occlusion time in patients with hepatocellular carcinoma complicated by post hepatitis B cirrhosis: a randomized controlled trial.2023Scandinavian journal of gastroenterologyRCT
  39. The diagnostic value of contrast-enhanced ultrasound LI-RADS for hepatocellular carcinoma in patients with cirrhosis and chronic hepatitis B.2022Abdominal radiology (New York)
  40. Molecular Mechanisms of Resistance to Tyrosine Kinase Inhibitors Associated with Hepatocellular Carcinoma.2022Current cancer drug targets
  41. Iodine-125 Seeds Inhibit Carcinogenesis of Hepatocellular Carcinoma Cells by Suppressing Epithelial-Mesenchymal Transition via TGF-β1/Smad Signaling.2022Disease markersFree full text
  42. Radiofrequency ablation in the treatment of hepatocellular carcinoma.2022International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group
  43. Risk factors for the recurrence of early hepatocellular carcinoma treated by percutaneous radiofrequency ablation with a multiple-electrode switching system: a multicenter prospective study.2022International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group
  44. Laparoscopic Anatomical Versus Non-anatomical hepatectomy in the Treatment of Hepatocellular Carcinoma: A randomised controlled trial.2022International journal of surgery (London, England)RCT
  45. The Short-Term Efficacy of Novel No-Touch Combined Directional Perfusion Radiofrequency Ablation in the Treatment of Small Hepatocellular Carcinoma with Cirrhosis.2022Journal of investigative surgery : the official journal of the Academy of Surgical Research
  46. TACE with portal vein radioactive seeds for HCC with portal vein tumor thrombus: a meta-analysis.2022Minimally invasive therapy & allied technologies : MITAT : official journal of the Society for Minimally Invasive Therapy
  47. Mutant Kras and mTOR crosstalk drives hepatocellular carcinoma development via PEG3/STAT3/BEX2 signaling.2022TheranosticsFree full text
  48. Laparoscopic liver resection for primary liver cancers originating in the paracaval portion of the caudate lobe: a preliminary retrospective analysis with 31 patients.2022Updates in surgery
  49. ASO Author Reflections: A New Minimally Invasive Procedure for Hepatocellular Carcinoma with Situs Inversus Totalis.2021Annals of surgical oncology
  50. Pure Laparoscopic Anatomic Right Hemihepatectomy for Hepatocellular Carcinoma with Situs Inversus Totalis Using Indocyanine Green Fluorescence Staining (with Video).2021Annals of surgical oncology
  51. Rescue radiofrequency ablation or percutaneous ethanol injection: a strategy for failed RALPPS stage-1 in patients with cirrhosis-related hepatocellular carcinoma.2021BMC surgeryFree full text
  52. FNDC4 acts as an extracellular factor to promote the invasiveness of hepatocellular carcinoma partly via the PI3K/Akt signalling pathway.2021Cancer medicineFree full text
  53. Hepatopulmonary syndrome delays postoperative recovery and increases pulmonary complications after hepatectomy.2021European journal of gastroenterology & hepatology
  54. T-lymphoma invasion and metastasis 1 promotes invadopodia formation and is regulated by the PI3K/Akt signaling pathway in hepatocellular carcinoma.2021Experimental cell research
  55. p53 haploinsufficiency and increased mTOR signalling define a subset of aggressive hepatocellular carcinoma.2021Journal of hepatology
  56. Advanced hepatocellular carcinoma treated by radiofrequency ablation combined with oncolytic virus and anti-PD-1 antibody therapy: a case report and literature review.2021The Journal of international medical researchFree full text
  57. Elevated FBXO45 promotes liver tumorigenesis through enhancing IGF2BP1 ubiquitination and subsequent PLK1 upregulation.2021eLifeFree full text
Chinese-language papers (not in the count)2
  1. [Study of a nomogram model of gadoxetate disodium-enhanced magnetic resonance imaging for the preoperative diagnosis of proliferative hepatocellular carcinoma and its value].2025Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatologyFree full text
  2. [Differentiation between hyperintense hepatocellular carcinoma and focal nodular hyperplasia in hepatobiliary phase with multimodal parameters of magnetic resonance imaging].2022Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatologyFree full text
All its trials on ClinicalTrials.gov, any status28
  1. Radiofrequency Ablation Plus Systematic Neoadjuvant Therapy for Recurrent Hepatocellular Carcinoma (RANT Study)Status unknownNCT05277675Lead sponsorN/AStart 2021-11
  2. A Study of Laparoscopic Middle Hepatic Vein Guidance and Traditional Anatomic HemihepatectomyStatus unknownNCT04422249Lead sponsorN/AStart 2019-12
  3. The Short-term Efficacy of Novel NTDP-RFA in the Treatment of Small HCC With Cirrhosis.Status unknownNCT04513119Lead sponsorStart 2017-01
  4. Efficacy and Safety of Sorafenib as Adjuvant and Latter Radiofrequency Ablation for Recurrent Hepatocellular CarcinomaStatus unknownNCT03097848Lead sponsorN/AStart 2017-05
  5. Radiofrequency Ablation Accompanied With Spontaneous Sorafenib in Early to Intermediate Stage HCCStatus unknownNCT02187081Lead sponsorN/AStart 2017-03
  6. No-touch RFA Versus Traditional RFA for Small Hepatocellular CarcinomaStatus unknownNCT02830737Lead sponsorN/AStart 2016-01
  7. By Using Adoptive Transfer of Autologous NK Cells to Prevent Recurrence of Hepatocellular Carcinoma After Curative TherapyStatus unknownNCT02725996Lead sponsorPhase 2Start 2016-04
  8. Radiofrequency Ablation Combined With Recombinant Human Adenovirus Type 5 in the Treatment of Hepatocellular Carcinoma.Status unknownNCT03790059Lead sponsorN/AStart 2016-10
  9. A Study of Laparoscopic Hepatectomy Versus RFA in the Treatment of Recurrent HCCStatus unknownNCT03313648Lead sponsorN/AStart 2016-09
  10. Combined Treatment of RFA and Sorafenib on Recurrent HCCStatus unknownNCT01470495Lead sponsorN/AStart 2015-01
  11. RALPPS Venus ALPPS for Hepatocellular CarcinomaStatus unknownNCT02299843Lead sponsorN/AStart 2014-10
  12. Radiofrequency-assisted Hepatectomy on the Outcomes of HCC Patients With CirrhosisStatus unknownNCT01992978Lead sponsorN/AStart 2013-11
  13. Radiofrequency Ablation Assisted Hepatectomy Versus Hepatectomy Alone for Advanced Hepatocellular CarcinomaStatus unknownNCT01713244Lead sponsorN/AStart 2012-10
  14. Treatment of Hepatocellular Carcinoma With Radiofrequency Ablation (RFA) Associated With Postoperative TACEStatus unknownNCT00730860Lead sponsorN/AStart 2009-12
  15. Effect of I/R Injuries by Pringle Manoeuvre on the Prognosis of HCC Patients After Curative HepatectomyCompletedNCT00725335Lead sponsorN/AStart 2008-09
  16. Laparoscopic Associating Liver Partition and Portal Vein Ligation for Staged HepatectomyStatus unknownNCT02203409Lead (inferred)Start 2014-07
  17. Recurrence Risk Factors of Early-Stage Hepatocellular Carcinoma After Radio Frequency AblationStatus unknownNCT02046356Lead (inferred)Start 2014-01
  18. Laparoscope Anatomical and Aon-anatomical HepatectomyStatus unknownNCT02009176Lead (inferred)N/AStart 2013-03
  19. Laparoscopic Hepatectomy Versus Open Hepatectomy for PHCCompletedNCT02014025Lead (inferred)N/AStart 2013-03
  20. Comparison of ultraSound, Abbreviated MRI witH and Without HBP aS mOdalities for HCC suRveillance in patienTs With High RiskNot yet recruitingNCT07010588Study siteN/AStart 2025-06
  21. Digital Early Warning System for Acute Lung Injury in Liver SurgeryRecruitingNCT07070362Study siteStart 2024-11
  22. A Study of TACE Combined With Atezolizumab Plus Bevacizumab or TACE Alone in Patients With Untreated Heaptocellular CarcionmaActive, not recruitingNCT04712643Study sitePhase 3Start 2021-03
  23. Evaluate the Safety and Efficacy of Toripalimab Combined With Bevacizumab Versus Sorafenib Therapy for HCCCompletedNCT04723004Study sitePhase 3Start 2020-10
  24. Prospective Surveillance for Very Early Hepatocellular CarcinomaStatus unknownNCT03588442Study siteStart 2018-07
  25. Hepatocellular Carcinoma Registry in Asia: The INSIGHT RegistryCompletedNCT03233360Study siteStart 2017-04
  26. the Efficacy and Safety of Ginsenoside Rg3 Capsule in Prevention of Postoperative Recurrence of Hepatocellular CarcinomaCompletedNCT01717066Study siteN/AStart 2012-11
  27. Phase 3 Study of ThermoDox With Radiofrequency Ablation (RFA) in Treatment of Hepatocellular Carcinoma (HCC)CompletedNCT00617981Study sitePhase 3Start 2008-05
  28. T138067 Versus Doxorubicin in Chemotherapy-Naive, Unresectable, Hepatocellular Carcinoma PatientsTerminatedNCT00057382Study sitePhase 2/Phase 3Start 2003-03

Run the PubMed searchClinicalTrials.gov

Cancer

Stomach cancer

胃癌

Led 23 of the 9,782 English-language PubMed papers on stomach cancer with an author in mainland China, 2021–2025: 0.2%.

Papers led
23
2021–2025
Trials led
9
any status, ClinicalTrials.gov
Open trials led
2
recruiting or about to
Open trials as a site
2
led by another institution
Papers led per year
2021: 101020212022: 5520222023: 2220232024: 4420242025: 112025

6 hospitals in Chongqing for stomach cancer218 hospitals in China for stomach cancer

Open trials with this hospital 4

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Robotic Versus Laparoscopic Radical Surgery for Locally Advanced Gastric Cancer
    Phase
    N/A
    Started
    2025-02
    Registry
    NCT06791538

    Age 18 years to 75 years (registered criteria)

    Led by Southwest Hospital, Army Medical UniversityChongqing

  2. Recruiting
    A Prospective Cohort Study on the Treatment of Locally Advanced Gastric Cancer
    Phase
    Not given
    Started
    2024-12
    Registry
    NCT06760858

    Age 18 years to 80 years (registered criteria)

    Led by Southwest Hospital, Army Medical UniversityChongqing

  3. Recruiting
    Radical Surgery Versus Non-Surgery in Gastric Cancer Patients With Peritoneal Metastasis After Successful Conversion Therapy
    Phase
    Phase 3
    Started
    2026-12
    Registry
    NCT07789184

    Age 18 years to 70 years (registered criteria)

    Lead sponsor is not a listed hospital; 25 listed hospitals as study sitesBeijing, Changchun, Chongqing, Dalian, Guangzhou, Hangzhou, Jinan, Nanchang, Nanjing, Qingdao, Shanghai, Tianjin, Urumqi, Wuhan, Xi'an

  4. Recruiting
    Clinical Study of Taurine Combined With Neoadjuvant Chemo-Immunotherapy for Treatment of Locally Advanced Gastric Cancer
    Phase
    N/A
    Started
    2024-09
    Registry
    NCT06128252

    Age 18 years to 75 years (registered criteria)

    Led by Tangdu Hospital; 11 listed hospitals as study sitesChongqing, Nanjing, Shanghai, Shenyang, Urumqi, Wuhan, Xi'an

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesSurgeryPeritoneal spread & advanced diseaseEarly detection & endoscopy
Departments in papersSurgery (general/hepatobiliary/pancreatic)Pathology / laboratory medicineGastroenterology / hepatology
Papers it led23
  1. Clinicopathological features and diagnostic challenges of early gastric cardiac carcinoma with dysplastic gastritis cystica profunda: A case report.2026Pathology, research and practice
  2. METTL1-WDR4 promotes the migration and proliferation of gastric cancer through N7-methylguanosine.2025Cellular oncology (Dordrecht, Netherlands)Free full text
  3. Lopinavir enhances anoikis by remodeling autophagy in a circRNA-dependent manner.2024AutophagyFree full text
  4. Association between textbook outcome and long-term survival among patients undergoing curative-intent resection of gastric cancer.2024Surgery
  5. Comparison of totally robotic and totally laparoscopic gastrectomy for gastric cancer: a propensity score matching analysis.2024Surgical endoscopy
  6. Long-term oncological outcomes of robotic versus laparoscopic gastrectomy for gastric cancer: multicentre cohort study.2024The British journal of surgery
  7. Robotic Gastrectomy Versus Laparoscopic Gastrectomy for Gastric Cancer: A Multicenter Cohort Study of 5402 Patients in China.2023Annals of surgery
  8. Long-term oncologic and surgical outcomes of robotic and laparoscopic gastrectomy for Siewert II/III esophagogastric junction carcinoma: A propensity score-matched retrospective cohort study.2023European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  9. FasL+ PD-L2+ Identifies a Novel Immunosuppressive Neutrophil Population in Human Gastric Cancer That Promotes Disease Progression.2022Advanced science (Weinheim, Baden-Wurttemberg, Germany)Free full text
  10. PLXDC2 enhances invadopodium formation to promote invasion and metastasis of gastric cancer cells via interacting with PTP1B.2022Clinical & experimental metastasisFree full text
  11. A comparative study on perioperative outcomes between robotic versus laparoscopic D2 total gastrectomy.2022International journal of surgery (London, England)
  12. Surgical and survival outcomes after laparoscopic and open gastrectomy for serosa-invasive Siewert type II/III esophagogastric junction carcinoma: a propensity score matching analysis.2022Surgical endoscopy
  13. Comparison of the Postoperative Complications Between Robotic Total and Distal Gastrectomies for Gastric Cancer Using Clavien-Dindo Classification: A Propensity Score-matched Retrospective Cohort Study of 726 Patients.2022Surgical innovation
  14. Activated neutrophils polarize protumorigenic interleukin-17A-producing T helper subsets through TNF-α-B7-H2-dependent pathway in human gastric cancer.2021Clinical and translational medicineFree full text
  15. Expression, regulation and clinical significance of B7-H3 on neutrophils in human gastric cancer.2021Clinical immunology (Orlando, Fla.)
  16. Upregulation of Tubulointerstitial nephritis antigen like 1 promotes gastric cancer growth and metastasis by regulating multiple matrix metallopeptidase expression.2021Journal of gastroenterology and hepatology
  17. Granulocyte-Macrophage Colony-Stimulating Factor-Activated Neutrophils Express B7-H4 That Correlates with Gastric Cancer Progression and Poor Patient Survival.2021Journal of immunology researchFree full text
  18. Laparoscopic versus open gastrectomy for serosa-invasive gastric cancer: A single-center retrospective cohort study.2021Surgery
  19. Incidence and risk factors of postoperative complications after robotic gastrectomy for gastric cancer: an analysis of 817 cases based on 10-year experience in a large-scale center.2021Surgical endoscopy
  20. Long-term oncologic outcomes of robotic versus laparoscopic gastrectomy for locally advanced gastric cancer: a propensity score-matched analysis of 1170 patients.2021Surgical endoscopy
  21. Morbidity and short-term surgical outcomes of robotic versus laparoscopic distal gastrectomy for gastric cancer: a large cohort study.2021Surgical endoscopy
  22. Learning curve of robotic distal and total gastrectomy.2021The British journal of surgery
  23. Gastric schwannoma treated by endoscopic full-thickness resection and endoscopic purse-string suture: A case report.2021World journal of gastroenterologyFree full text
Chinese-language papers (not in the count)3
  1. [Preliminary Investigation of the Molecular Mechanism of Empagliflozin Suppressing Gastric Cancer Through Mammalian Target of Rapamycin].2023Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science editionFree full text
  2. [Future prospect of robotic gastric cancer surgery].2022Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  3. [Comparison of clinical efficacy and quality of life between uncut Roux-en-Y and Billroth II with Braun anastomosis in laparoscopic distal gastrectomy for gastric cancer].2022Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
All its trials on ClinicalTrials.gov, any status16
  1. Robotic Versus Laparoscopic Radical Surgery for Locally Advanced Gastric CancerRecruitingNCT06791538Lead sponsorN/AStart 2025-02
  2. A Prospective Cohort Study on the Treatment of Locally Advanced Gastric CancerRecruitingNCT06760858Lead sponsorStart 2024-12
  3. Robotic and Laparoscopic Total Gastrectomy With D2 Lymphadenectomy for Locally Advanced Gastric CancerCompletedNCT03500471Lead sponsorStart 2018-04
  4. Robotic Versus Laparoscopic Distal Gastrectomy With D2 Lymphadenectomy for Locally Advanced Gastric CancerStatus unknownNCT03273920Lead sponsorN/AStart 2017-09
  5. A Clinical Research of CAR T Cells Targeting CEA Positive CancerStatus unknownNCT02349724Lead sponsorPhase 1Start 2014-12
  6. Long-term Oncologic Outcomes of Robotic Versus Laparoscopic Total Gastrectomy for Advanced Gastric CancerCompletedNCT05181306Lead sponsorStart 2010-10
  7. Comparison of Vagus Nerve-preserving RADG and Conventional RADG for AGCStatus unknownNCT02806661Lead (inferred)N/AStart 2016-07
  8. A Clinical Research of CAR T Cells Targeting HER2 Positive CancerWithdrawnNCT02713984Lead (inferred)Phase 1/Phase 2Start 2016-03
  9. Comparison of Laparoscopic Versus Open Gastrectomy for Advanced Gastric Cancer:A Prospective Randomized TrialStatus unknownNCT01043835Lead (inferred)N/AStart 2010-02
  10. Radical Surgery Versus Non-Surgery in Gastric Cancer Patients With Peritoneal Metastasis After Successful Conversion TherapyRecruitingNCT07789184Study sitePhase 3Start 2026-12
  11. Clinical Study of Taurine Combined With Neoadjuvant Chemo-Immunotherapy for Treatment of Locally Advanced Gastric CancerRecruitingNCT06128252Study siteN/AStart 2024-09
  12. Laparoscopic D2 Distal Gastrectomy Following Neoadjuvant Chemotherapy for Locally Advanced Gastric CancersStatus unknownNCT03468712Study siteN/AStart 2018-03
  13. Incidence of Pancreatic Fistula After Radical GastrectomyStatus unknownNCT03391687Study siteStart 2017-12
  14. Study on Laparoscopic Spleen-Preserving No. 10 Lymph Node Dissection for Advanced Gastric CancerStatus unknownNCT02845986Study sitePhase 2Start 2016-09
  15. Nasal Endoscopic Screening and Risk Assessment for Early Gastric CancerStatus unknownNCT04989153Study siteStart 2016-03
  16. Roux-en-Y vs. Roux-en-Y+ Pouch for D2 Total GastrectomyStatus unknownNCT02110628Study sitePhase 3Start 2014-08

Run the PubMed searchClinicalTrials.gov

Cancer

Osteosarcoma

骨肉瘤

Led 7 of the 2,257 English-language PubMed papers on osteosarcoma with an author in mainland China, 2021–2025: 0.3%.

Papers led
7
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 2220212022: 0020222023: 4420232024: 1120242025: 002025

23 hospitals in Chongqing for osteosarcoma742 hospitals in China for osteosarcoma

No open trial on osteosarcoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersPathology / laboratory medicine
Papers it led7
  1. Inhibitors of APE1 redox and ATM synergistically sensitize osteosarcoma cells to ionizing radiation by inducing ferroptosis.2024International immunopharmacology
  2. Tantalum-Zirconium Co-Doped Metal-Organic Frameworks Sequentially Sensitize Radio-Radiodynamic-Immunotherapy for Metastatic Osteosarcoma.2023Advanced science (Weinheim, Baden-Wurttemberg, Germany)
  3. Retrospective review of safety and efficacy of anlotinib in advanced osteosarcoma with metastases after failure of standard multimodal therapy.2023Asia-Pacific journal of clinical oncology
  4. Extracellular vesicles in tumorigenesis, metastasis, chemotherapy resistance and intercellular communication in osteosarcoma.2023Bioengineered
  5. An Exploration of Osteosarcoma Metastasis Diagnostic Markers Based on Tumor-Associated Neutrophils.2023Discovery medicine
  6. Circular RNA circ-CHI3L1.2 modulates cisplatin resistance of osteosarcoma cells via the miR-340-5p/LPAATβ axis.2021Human cell
  7. Comparative efficacy of intraoperative extracorporeal irradiated and alcohol-inactivated autograft reimplantation for the management of osteosarcomas-a multicentre retrospective study.2021World journal of surgical oncology
Chinese-language papers (not in the count)1
  1. [Advances in the pathology of bone lesions in China over the past ten years: retrospect and prospect].2025Zhonghua bing li xue za zhi = Chinese journal of pathology
Earlier papers (2016–2020)3
  1. Calponin 3 is associated with poor prognosis and regulates proliferation and metastasis in osteosarcoma.2020Aging
  2. Long noncoding RNA OIP5-AS1 causes cisplatin resistance in osteosarcoma through inducing the LPAATβ/PI3K/AKT/mTOR signaling pathway by sponging the miR-340-5p.2019Journal of cellular biochemistry
  3. LncRNA LINC00628 overexpression inhibits the growth and invasion through regulating PI3K/Akt signaling pathway in osteosarcoma.2018European review for medical and pharmacological sciences

Run the PubMed searchClinicalTrials.gov

Cancer

Gastrointestinal stromal tumour

胃肠道间质瘤

Led 1 of the 523 English-language PubMed papers on gastrointestinal stromal tumour with an author in mainland China, 2021–2025: 0.2%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 0020222023: 0020232024: 0020242025: 002025

11 hospitals in Chongqing for gastrointestinal stromal tumour261 hospitals in China for gastrointestinal stromal tumour

No open trial on gastrointestinal stromal tumour lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersGastroenterology / hepatology

Run the PubMed searchClinicalTrials.gov

Cancer

Neuroblastoma

神经母细胞瘤

Led no English-language PubMed papers on neuroblastoma in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

10 hospitals in Chongqing for neuroblastoma352 hospitals in China for neuroblastoma

No open trial on neuroblastoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Blood disorders

Multiple myeloma

多发性骨髓瘤

Led no English-language PubMed papers on multiple myeloma in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
1
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution

4 hospitals in Chongqing for multiple myeloma178 hospitals in China for multiple myeloma

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Not yet recruiting
    Clinical Study of TQB2934 Injection in Relapsed/Refractory Multiple Myeloma
    Phase
    Phase 3
    Started
    2026-06
    Registry
    NCT07569757

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 38 listed hospitals as study sitesBeijing, Bengbu, Changsha, Chengde, Chengdu, Chongqing, Guangzhou, Guiyang, Hangzhou, Harbin, Hefei, Jinan, Kunming, Lanzhou, Luzhou, Nanchang, Nanjing, Nanning, Qingdao, Shanghai, Shenyang, Shijiazhuang, Taiyuan, Xi'an, Xuzhou, Zhanjiang, Zhengzhou, Zhuzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
All its trials on ClinicalTrials.gov, any status2
  1. A Clinical Research of BCMA-Targeted CAR-T in B Cell MalignanciesStatus unknownNCT02954445Lead sponsorPhase 1/Phase 2Start 2016-10
  2. Clinical Study of TQB2934 Injection in Relapsed/Refractory Multiple MyelomaNot yet recruitingNCT07569757Study sitePhase 3Start 2026-06

Run the PubMed searchClinicalTrials.gov

Blood disorders

Aplastic anaemia

再生障碍性贫血

Led 2 of the 412 English-language PubMed papers on aplastic anaemia with an author in mainland China, 2021–2025: 0.5%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 1120242025: 002025

4 hospitals in Chongqing for aplastic anaemia63 hospitals in China for aplastic anaemia

No open trial on aplastic anaemia lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
Departments in papersPathology / laboratory medicine

Run the PubMed searchClinicalTrials.gov

Blood disorders

Haemophagocytic lymphohistiocytosis

噬血细胞性淋巴组织细胞增生症

Led 2 of the 399 English-language PubMed papers on haemophagocytic lymphohistiocytosis with an author in mainland China, 2021–2025: 0.5%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 2220232024: 0020242025: 002025

4 hospitals in Chongqing for haemophagocytic lymphohistiocytosis66 hospitals in China for haemophagocytic lymphohistiocytosis

No open trial on haemophagocytic lymphohistiocytosis lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesLymphoma & cancer-related HLHGenetics & inherited forms

Run the PubMed searchClinicalTrials.gov

Blood disorders

Atypical haemolytic uraemic syndrome

非典型溶血性尿毒症综合征

Led no English-language PubMed papers on atypical haemolytic uraemic syndrome in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

1 hospital in Chongqing for atypical haemolytic uraemic syndrome31 hospitals in China for atypical haemolytic uraemic syndrome

No open trial on atypical haemolytic uraemic syndrome lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Earlier papers (2016–2020)1
  1. Genetic Analysis of 400 Patients Refines Understanding and Implicates a New Gene in Atypical Hemolytic Uremic Syndrome.2018Journal of the American Society of Nephrology : JASN

Run the PubMed searchClinicalTrials.gov

Blood disorders

Fanconi anaemia

范可尼贫血

Led 1 of the 68 English-language PubMed papers on Fanconi anaemia with an author in mainland China, 2021–2025: 1.5%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 1120242025: 002025

2 hospitals in Chongqing for Fanconi anaemia40 hospitals in China for Fanconi anaemia

No open trial on Fanconi anaemia lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersPathology / laboratory medicine

Run the PubMed searchClinicalTrials.gov

Other diseases

Moyamoya disease

烟雾病

Led 2 of the 356 English-language PubMed papers on moyamoya disease with an author in mainland China, 2021–2025: 0.6%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 1120242025: 112025

1 hospital in Chongqing for moyamoya disease47 hospitals in China for moyamoya disease

No open trial on moyamoya disease lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesImaging & blood flowGenetics
Departments in papersNeurosurgeryNeurology

Run the PubMed searchClinicalTrials.gov

Other diseases

Amyotrophic lateral sclerosis

肌萎缩侧索硬化症

Led 1 of the 779 English-language PubMed papers on amyotrophic lateral sclerosis with an author in mainland China, 2021–2025: 0.1%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 0020222023: 0020232024: 0020242025: 002025

6 hospitals in Chongqing for amyotrophic lateral sclerosis194 hospitals in China for amyotrophic lateral sclerosis

No open trial on amyotrophic lateral sclerosis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

Duchenne muscular dystrophy

杜氏肌营养不良

Led no English-language PubMed papers on Duchenne muscular dystrophy in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

5 hospitals in Chongqing for Duchenne muscular dystrophy116 hospitals in China for Duchenne muscular dystrophy

No open trial on Duchenne muscular dystrophy lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Chinese-language papers (not in the count)1
  1. [Application of multi-technique in combined for the detection and prenatal diagnosis of families affected with Duchenne muscular dystrophy].2025Zhonghua yi xue yi chuan xue za zhi = Zhonghua yixue yichuanxue zazhi = Chinese journal of medical genetics

Run the PubMed searchClinicalTrials.gov

Other diseases

Behçet disease

白塞病

Led 1 of the 245 English-language PubMed papers on Behçet disease with an author in mainland China, 2021–2025: 0.4%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 0020222023: 0020232024: 0020242025: 002025

7 hospitals in Chongqing for Behçet disease149 hospitals in China for Behçet disease

No open trial on Behçet disease lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersGastroenterology / hepatology

Run the PubMed searchClinicalTrials.gov

Other diseases

IgA nephropathy

IgA 肾病

Led no English-language PubMed papers on IgA nephropathy in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

14 hospitals in Chongqing for IgA nephropathy346 hospitals in China for IgA nephropathy

No open trial on IgA nephropathy lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
All its trials on ClinicalTrials.gov, any status1
  1. A Study of Telitacicept for IgA Nephropathy (TELIGAN)Active, not recruitingNCT05799287Study sitePhase 3Start 2023-04

Run the PubMed searchClinicalTrials.gov

Other diseases

Primary biliary cholangitis

原发性胆汁性胆管炎

Led 5 of the 300 English-language PubMed papers on primary biliary cholangitis with an author in mainland China, 2021–2025: 1.7%.

Papers led
5
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 3320232024: 1120242025: 002025

5 hospitals in Chongqing for primary biliary cholangitis173 hospitals in China for primary biliary cholangitis

No open trial on primary biliary cholangitis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersGastroenterology / hepatology

Over half of these papers are lab or animal studies.

Run the PubMed searchClinicalTrials.gov

Other diseases

Primary sclerosing cholangitis

原发性硬化性胆管炎

Led 1 of the 100 English-language PubMed papers on primary sclerosing cholangitis with an author in mainland China, 2021–2025: 1.0%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 0020242025: 002025

1 hospital in Chongqing for primary sclerosing cholangitis90 hospitals in China for primary sclerosing cholangitis

No open trial on primary sclerosing cholangitis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Papers it led1
  1. Causal effect of autoimmune liver diseases on cancer: Meta-analyses of cohort studies and Mendelian randomization study.2022Liver international : official journal of the International Association for the Study of the Liver

Run the PubMed searchClinicalTrials.gov

Other diseases

Inherited epidermolysis bullosa

遗传性大疱性表皮松解症

Led no English-language PubMed papers on inherited epidermolysis bullosa in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

4 hospitals in Chongqing for inherited epidermolysis bullosa41 hospitals in China for inherited epidermolysis bullosa

No open trial on inherited epidermolysis bullosa lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Earlier papers (2016–2020)1
  1. Novel biallelic variants in COL7A1 cause recessive dystrophic epidermolysis bullosa.2020Molecular genetics & genomic medicine

Run the PubMed searchClinicalTrials.gov

Getting in touch

Name card to show staff or a driver

陆军军医大学第一附属医院(西南医院)

Southwest Hospital, Army Medical University

重庆

Large hospitals often have several campuses. Confirm the campus with the hospital before travelling.

Inquiry letter in English and Chinese

Fill in the brackets, then send it through the contact options on the hospital's international office or official website. Nothing typed here leaves this device.

Records hospitals usually ask for

  • A recent summary or letter from the treating doctor
  • Pathology report
  • Scans (CT, MRI, PET) with their reports, and the images if possible
  • Treatments so far, with dates
  • Current medicines

What to do next

Talk with the treating doctorThis page can be shared with the treating doctor to discuss whether this team's work is relevant.
Check the team is still therePapers lag by months and doctors move. Look for the department on the hospital's own website.
Contact the hospital directlyUse the hospital's own contacts. Hospitals never pay us, and each hospital decides which patients it accepts.

Where these numbers come from

Papers

English-language PubMed papers whose first or last author lists this hospital as their first affiliation, 2021–2025. Definitions

Trials

ClinicalTrials.gov records naming this hospital as lead sponsor or site, as of 8 Nov 2026.

Identifiers and other names

ROR
Southwest Hospital; First Affiliated Hospital (Southwest Hospital); First Affiliated Hospital of Army Medical University; Southwest Hospital Affiliated to Third Military Medical University; Southwest Hospital of the Third Military Medical University; Southwest Hospital of Army Medical University; First Affiliated Hospital of the Army Medical University; First Affiliated Hospital, Third Military Medical University

Suggest a correctionDownload the data